Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-5001A is a long-acting injectable (LAI) formulation of donepezil, a reversible acetylcholinesterase inhibitor, developed by G2G Bio for the treatment of Alzheimer's disease. The drug utilizes G2G Bio's proprietary InnoLamp (Innovative Long-Acting MicroParticle) technology to create a sustained-release microsphere formulation. This delivery system is designed to maintain therapeutic plasma concentrations of donepezil for one month following a single administration, aiming to improve medication adherence and minimize the gastrointestinal side effects typically associated with the peak plasma levels of daily oral dosing. GB-5001A is part of a broader program (GB-5001) that has undergone early-stage clinical evaluation to demonstrate bioequivalence and safety compared to oral donepezil.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GB-5001A.